Invex Therapeutics (ASX:IXC) Accounts Payable: A$0.18 Mil (As of Dec. 2025)


What is Invex Therapeutics Accounts Payable?

Invex Therapeutics ASX:IXC Accounts Payable is A$0.18 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Invex Therapeutics's Accounts Payable for the quarter that ended in Dec. 2025 was A$0.18 Mil.

Invex Therapeutics's quarterly Accounts Payable declined from Dec. 2024 (A$0.48 Mil) to Jun. 2025 (A$0.17 Mil) but then increased from Jun. 2025 (A$0.17 Mil) to Dec. 2025 (A$0.18 Mil).

Invex Therapeutics's annual Accounts Payable declined from Jun. 2023 (A$1.14 Mil) to Jun. 2024 (A$0.01 Mil) but then increased from Jun. 2024 (A$0.01 Mil) to Jun. 2025 (A$0.17 Mil).

Invex Therapeutics Accounts Payable Related Terms

Invex Therapeutics Accounts Payable Historical Data

* Premium members only.

The historical data trend for Invex Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invex Therapeutics Accounts Payable Chart

Invex Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Accounts Payable
Get a 7-Day Free Trial 0.01 0.14 1.14 0.01 0.17

Invex Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.99 0.01 0.48 0.17 0.18

Invex Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of A$0.18 Mil mean?
Invex Therapeutics (ASX:IXC) has a Accounts Payable of A$0.18 Mil as of Dec. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Invex Therapeutics and its competitors.
Is Invex Therapeutics' Accounts Payable too high?
Invex Therapeutics' current Accounts Payable is A$0.18 Mil.
How does Invex Therapeutics' Accounts Payable compare to VRTX and REGN?
Invex Therapeutics' Accounts Payable of A$0.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Invex Therapeutics and its competitors. Invex Therapeutics's current Accounts Payable is A$0.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current Accounts Payable of A$0.18 Mil. The current Accounts Payable is A$0.18 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current Accounts Payable is A$0.18 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invex Therapeutics Business Description

Address c/- Automic Group, Level 5, 191 St Georges Terrace, Perth, WA, AUS, 6000
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.